Business Wire
Almac publishes breast cancer chemotherapy response assay in the
Tuesday, 21 January 2014 01:06
De Facto CommunicationsTristan Jervis This e-mail address is being protected from spambots. You need JavaScript enabled to view it T: 00 44 207 861 3019M: 00 44 771 363 8396orAlmacAustin Tanney This e-mail address is being protected from spambots. You need JavaScript enabled to view it T: 00 44 2838 337575
Read more...
 
CytRx Receives FDA Approval to Extend Aldoxorubicin Dosing Cycles until Disease Progression in Upcoming Pivotal, Global Phase 3 Trial for Soft Tissue Sarcomas
Tuesday, 21 January 2014 01:06
Additional treatment cycles create potential for substantially improved efficacy results
Read more...
 
Illumina Signs Master Supply Agreement to Provide Next-Generation Sequencing Technologies to LabCorp®
Tuesday, 21 January 2014 01:06
Illumina, Inc.Investors:Rebecca Chambers858-255-5243 This e-mail address is being protected from spambots. You need JavaScript enabled to view it orMedia:Jennifer Temple858-882-6822 This e-mail address is being protected from spambots. You need JavaScript enabled to view it
Read more...
 
Acceleron Commences Proposed Public Offering of Common Stock
Tuesday, 21 January 2014 01:06
Read more...
 
FDA Grants Orphan Drug Designation to Soliris® (eculizumab) for Prevention of Delayed Graft Function (DGF) in Renal Transplant Patients
Tuesday, 21 January 2014 01:06
Alexion Pharmaceuticals, Inc.Irving Adler, 203-271-8210Exec. Director, Corporate CommunicationsorKim Diamond, 203-439-9600Senior Director, Corporate CommunicationsorInvestors:Rx CommunicationsRhonda Chiger, 917-322-2569
Read more...
 
Alitair Announces Issuance of an Additional Patent Covering its Platform Drug Delivery Technology, REA™
Tuesday, 21 January 2014 01:05
Read more...
 
XenoPort Announces Proposed Public Offering of Common Stock
Tuesday, 21 January 2014 00:07
XenoPortJackie Cossmon, 408-616-7220 This e-mail address is being protected from spambots. You need JavaScript enabled to view it
Read more...
 
Affymetrix Receives FDA Clearance of First-of-its-kind Postnatal Test for Developmental Delays and Intellectual Disabilities in Children
Tuesday, 21 January 2014 00:07
CytoScan® Dx Assay represents a technology leap over traditional postnatal genetic tests and significantly improves diagnostic capability
Read more...
 
ISET 2014: Three-Year Data Shows Stent Treatment of Blocked Leg Arteries Lasts, Helps Patients Maintain Improved Quality of Life
Tuesday, 21 January 2014 00:05
Read more...
 
Three-Year Clinical Outcomes from STROLL Trial Demonstrate Sustained Durability and Performance of S.M.A.R.T.® Stent for Treatment of Peripheral Artery Disease
Tuesday, 21 January 2014 00:05
Read more...
 
Society for Thoracic Surgeons Annual Meeting
  • Pharmacy Times and Specialty Pharmacy Times Expand Strategic Alliance Partnership Program
  • MaxCyte Introduces the 2014 MaxCyte STX Scalable Transfection System for Cell-based Assay Applications at the SLAS 2014 Annual Conference & Exhibition
  • Provision Treats First Proton Therapy Patients in Tennessee
  • Cross-Functional Communication of Pharmaceutical Regulatory Strategy Boosts Organizational Impact
  • In Honor of Martin Luther King, Jr. Day: Bayer Re-Issues Recipe for Building a Diverse U.S. Innovation Generation
  • SafeBridge Consultants, Inc. Announces “Potent Compound Safety Certification” Approval of Corden Pharma Colorado API Manufacturing Location
  • RBCC Moves to the Front Lines of the 3D Bioprinting Revolution
  • PerkinElmer Introduces Novel Research Tools to Accelerate Discovery of More Effective Therapies for Life Threatening Diseases at the Society for Laboratory Automation and Screening (SLAS) 2014 Conference
  • Healthstat Hosts Grand Opening of Onsite Health Clinic at Jackson Rancheria Casino Resort
  • << Start < Prev 4681 4682 4683 4684 4685 4686 4687 4688 4689 4690 Next > End >>

    Page 4689 of 4744
    BMR:1